Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HydroWrap is an advanced, biocompatible hydrogel-based drug delivery system designed to address impaired fracture healing in patients with type 2 diabetes mellitus (T2DM). It functions as a smart hydrogen sulfide (H2S) delivery controller that modulates macrophage senescence within the compromised bone microenvironment. The system features a dual-responsive mechanism: it undergoes thermal contraction under near-infrared (NIR) irradiation to trigger rapid H2S release and provides sustained, glucose-responsive H2S generation in hyperglycemic conditions. By restoring H2S levels, HydroWrap alleviates mitochondrial dysfunction, suppresses senescence-associated secretory phenotypes (SASP), and promotes mitophagy, thereby interrupting the senescence cascade and enhancing bone quality and recovery time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HydroWrap.